Nanosynex is developing solutions designed to improve testing quality and reduce healthcare costs by accelerating diagnostic processes.Nanosynex is focused on the development and commercialization of an innovative antimicrobial susceptibility test (AST).

The technology is based on a purely phenotypic approach and uses a microfluidic disposable test cartridge platform and method that optimizes bacterial growth.The Nanosynex solution comprises a disposable test platform, hardware, and analysis software.

The product will allow laboratories to perform and provide results for same-day antimicrobial susceptibility tests, enabling doctors to create targeted, personalized antibiotic prescriptions for their patients.The companys technology stems from research discoveries made in the lab of Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion.